journal article·2023-01Open access

Developing Next‐Generation Protein‐Based Vaccines Using High‐Affinity Glycan Ligand‐Decorated Glyconanoparticles

Yanan Gao, Wei Wang, Yunru Yang, Qingyu Zhao, Chendong Yang, Xiaoying Jia, Yang Liu, Minmin Zhou, Weihong Zeng, Xuefei Huang, Sandra Chiu, Tengchuan Jin, Xuanjun Wu

Advanced Science· Volume 10· Issue 2

Abstract

Abstract Major diseases, such as cancer and COVID‐19, are frightening global health problems, and sustained action is necessary to develop vaccines. Here, for the first time, ethoxy acetalated dextran nanoparticles (Ace‐Dex‐NPs) are functionalized with 9‐N‐(4H‐thieno[3,2‐c]chromene‐2‐carbamoyl)‐Siaα2−3Galβ1−4GlcNAc (TCCSia‐LacNAc) targeting macrophages as a universal vaccine design platform. First, azide‐containing oxidized Ace‐Dex‐NPs are synthesized. After the NPs are conjugated with ovalbumin (OVA) and resiquimod (Rd), they are coupled to TCCSia‐LacNAc‐DBCO to produce TCCSia‐Ace‐Dex‐OVA‐Rd, which induce a potent, long‐lasting OVA‐specific cytotoxic T‐lymphocyte (CTL) response and high anti‐OVA IgG, providing mice with superior protection against tumors. Next, this strategy is exploited to develop vaccines against infection by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). The receptor‐binding domain (RBD) of the SARS‐CoV‐2 spike protein is the main target for neutralizing antibodies. The TCCSia‐Ace‐Dex platform is preferentially used for designing an RBD‐based vaccine. Strikingly, the synthetic TCCSia‐Ace‐Dex‐RBD‐Rd elicited potent RBD‐neutralizing antibodies against live SARS‐CoV‐2 infected Vero E6 cells. To develop a universal SARS‐CoV‐2 vaccine, the TCCSia‐Ace‐Dex‐N‐Rd vaccine carrying SARS‐CoV‐2 nucleocapsid protein (N) is also prepared, which is highly conserved among SARS‐CoV‐2 and its variants of concern (VOCs), including Omicron (BA.1 to BA.5); this vaccine can trigger strong N‐specific CTL responses against target cells infected with SARS‐CoV‐2 and its VOCs.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · SARS-CoV-2 and COVID-19 Research · vaccines and immunoinformatics approaches

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Glycoengineering Research Center Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate‐based Medicine Shandong University Qingdao Shandong 266237 China

State Key Laboratory of Virology Wuhan Institute of Virology Center for Biosafety Mega‐Science Chinese Academy of Sciences Wuhan 430071 China

University of the Chinese Academy of Sciences Beijing 100049 China

Department of Basic Medical Sciences Division of Molecular Medicine Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui 230001 China

Departments of Chemistry and Biomedical Engineering Institute for Quantitative Health Science and Engineering Michigan State University East Lansing Michigan 48824 United States

Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui 230001 China

Suzhou Research Institute Shandong University Suzhou Jiangsu 215123 China

Funding

Natural Science Foundation of Shandong Province · National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province

References (55)

Show source-provided references
1. 10.1126/science.123291010.1126/science.1232910 ↗
2. 10.1016/j.cell.2021.09.01010.1016/j.cell.2021.09.010 ↗
3. 10.1056/NEJMoa211945110.1056/NEJMoa2119451 ↗
4. c)GISAID Variant: 21K (Omicron) https://covariants.org/variants/21K.Omicron(accessed: October 2022).
5. 10.3389/fchem.2020.0028410.3389/fchem.2020.00284 ↗
6. 10.1002/anie.20210861010.1002/anie.202108610 ↗
7. 10.1039/c3cs35470a10.1039/c3cs35470a ↗
8. 10.1021/acs.chemrev.9b0047210.1021/acs.chemrev.9b00472 ↗
9. 10.1021/jacs.8b0847310.1021/jacs.8b08473 ↗
10. 10.1039/D0CC08265A10.1039/D0CC08265A ↗
11. 10.1038/s41586-020-2599-810.1038/s41586-020-2599-8 ↗
12. 10.1016/j.addr.2021.01.00110.1016/j.addr.2021.01.001 ↗
13. 10.1056/NEJMoa220226110.1056/NEJMoa2202261 ↗
14. 10.1038/s41392-022-00937-910.1038/s41392-022-00937-9 ↗
15. 10.1126/scitranslmed.abj530510.1126/scitranslmed.abj5305 ↗
16. 10.1056/NEJMoa210765910.1056/NEJMoa2107659 ↗
17. 10.1021/acs.chemrev.6b0053210.1021/acs.chemrev.6b00532 ↗
18. 10.1021/ja803947s10.1021/ja803947s ↗
19. 10.1016/j.biomaterials.2021.12079210.1016/j.biomaterials.2021.120792 ↗
20. 10.1007/s00018-021-04039-710.1007/s00018-021-04039-7 ↗
21. 10.1021/am300888810.1021/am3008888 ↗
22. 10.1002/adfm.20210505910.1002/adfm.202105059 ↗
23. 10.1039/D1CC00811K10.1039/D1CC00811K ↗
24. 10.1021/ja307501e10.1021/ja307501e ↗
25. 10.1371/journal.pone.003903910.1371/journal.pone.0039039 ↗
26. 10.1073/pnas.121988811010.1073/pnas.1219888110 ↗
27. 10.1016/j.chembiol.2018.10.00610.1016/j.chembiol.2018.10.006 ↗
28. 10.1073/pnas.090159210610.1073/pnas.0901592106 ↗
29. 10.1021/bc100596w10.1021/bc100596w ↗
30. 10.1021/acs.jmedchem.9b0063410.1021/acs.jmedchem.9b00634 ↗
31. 10.1021/ja056169010.1021/ja0561690 ↗
32. 10.1016/j.bmc.2004.09.03010.1016/j.bmc.2004.09.030 ↗
33. 10.1038/nchembio71310.1038/nchembio713 ↗
34. 10.1073/pnas.88.9.397210.1073/pnas.88.9.3972 ↗
35. 10.1073/pnas.89.13.602010.1073/pnas.89.13.6020 ↗
36. 10.1016/j.ymeth.2013.02.00710.1016/j.ymeth.2013.02.007 ↗
37. 10.1002/cmdc.20170064610.1002/cmdc.201700646 ↗
38. WHO WHO Coronavirus (COVID‐19) Dashboard https://covid19.who.int/(accessed: October 2022).
39. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
40. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
41. 10.1056/NEJMoa210529010.1056/NEJMoa2105290 ↗
42. 10.1016/S0140-6736(20)31208-310.1016/S0140-6736(20)31208-3 ↗
43. 10.1038/s41586-020-2798-310.1038/s41586-020-2798-3 ↗
44. FDA COVID‐19 vaccines https://www.fda.gov/emergency‐preparedness‐and‐response/coronavirus‐disease‐2019‐covid‐19/covid‐19‐vaccines(accessed: September 2022).
45. 10.1097/INF.000000000000323510.1097/INF.0000000000003235 ↗
46. 10.1038/d41586-021-00940-010.1038/d41586-021-00940-0 ↗
47. 10.1038/s41579-020-00462-y10.1038/s41579-020-00462-y ↗
48. 10.1038/s41591-022-01753-y10.1038/s41591-022-01753-y ↗
49. 10.1126/science.abn759110.1126/science.abn7591 ↗
50. 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7 ↗
51. 10.1128/JVI.01925-1910.1128/JVI.01925-19 ↗
52. 10.1016/j.bbrc.2020.04.13610.1016/j.bbrc.2020.04.136 ↗
53. 10.1038/s41541-021-00321-810.1038/s41541-021-00321-8 ↗
54. 10.1016/j.jconrel.2017.11.03010.1016/j.jconrel.2017.11.030 ↗
55. 10.4049/jimmunol.200128710.4049/jimmunol.2001287 ↗